Context Therapeutics Inc. CNTX
0.20 USD -0.02 (-7.13%)
Nov 12, 2026, 11:50 AM EST
0.196 Day range 0.214
0.18 52-week range 3.62
- YTD
- -86.35%
- 1 year
- -82.99%
Benzinga news
benzinga.com Context Therapeutics Q3 EPS $(0.08) Beats $(0.11) Estimate Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 20 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser…
benzinga.com Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipeline.
benzinga.com Context Therapeutics Q2 EPS $(0.15) Misses $(0.09) Estimate Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.09) by 66.67 percent. This is a 66.67 percent decrease over losses…
benzinga.com Context Therapeutics Added To Russell 2000, Russell 3000 Indexes, Effective June 26 Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today- benzinga.com Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4 Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $8 to $4.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with favorable safety data.
benzinga.com Context Therapeutics Announces Interim Phase 1 Clinical Data For CLDN6 X CD3 T Cell Engaging Bispecific Antibody, CTIM-76, In Advanced, Late-Line Platinum-Resistant Ovarian Cancer 29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer ("PROC") who progressed on a median of 7 prior lines of therapyCytokine Release Syndrome ("CRS")…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 80 percent decrease over losses of…
benzinga.com Context Therapeutics Receives FDA's Fast Track Designation For CTIM-76 To Treat Platinum-Resistant Ovarian Cancer Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target Guggenheim analyst Paul Jeng reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price target.
benzinga.com Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7 Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight and raises the price target from $4 to $7.- benzinga.com Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 34.62 percent.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket 
benzinga.com This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7 Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.
- benzinga.com D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5 HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.
- benzinga.com Context Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 9.89 percent. This is a 54.55 percent increase over losses…
- benzinga.com D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.
benzinga.com Context Therapeutics To Present Cancer Immunotherapy Data At SITC 2025 Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today…
benzinga.com This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - benzinga.com Cantor Fitzgerald Initiates Coverage On Context Therapeutics with Overweight Rating Cantor Fitzgerald analyst Li Watsek initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Overweight rating.
- benzinga.com Guggenheim Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $5 Guggenheim analyst Paul Jeng initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $5.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7%…
- benzinga.com Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today’s session.
- benzinga.com Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 498 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 345 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 175 stocks hit new 52-week lows.
- benzinga.com $7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders…
benzinga.com Insiders Buying AmeriServ Financial And 2 Other Penny Stocks The Dow Jones dropped by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in…- benzinga.com Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 127 companies set new 52-week lows.
- benzinga.com Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 930 stocks hit new 52-week lows.
- benzinga.com 66 Biggest Movers From Friday Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.